U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1320
    +0.0108 (+0.96%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3338
    +0.0018 (+0.14%)
     
  • USD/JPY

    113.3100
    -2.0290 (-1.76%)
     
  • BTC-USD

    54,695.30
    +39.35 (+0.07%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Philadelphia, Pennsylvania--(Newsfile Corp. - October 15, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period").

If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Michael Dell'Angelo at mdellangelo@bm.net or (215) 875-3080.

Whistleblowers: Anyone with non-public information regarding Cassava is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

According to recently filed lawsuits, Cassava and members of senior management misrepresented the quality and integrity of the scientific data supporting the Company's claims regarding the efficacy of its Alzheimer's drug, simufilam.

On August 24, 2021, reports surfaced that a citizen petition was submitted to the FDA raising serious concerns about the quality and integrity of the studies surrounding simufilam. The petition further identified "errors and anomalies" in the data "of a sufficient frequency and magnitude to strongly suggest scientific misconduct." As additional facts came to light regarding Cassava's clinical trial, the price of the Company's shares declined precipitously, from a closing price of $117.83 on August 24, 2021 to a closing price of $58.34 per share on August 27 - a decline of 50%.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Michael Dell'Angelo, Managing Shareholder
Berger Montague
(215) 875-3080
mdellangelo@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99814